209 related articles for article (PubMed ID: 29283894)
1. Incretin-based Drugs and the Incidence of Colorectal Cancer in Patients with Type 2 Diabetes.
Abrahami D; Yin H; Yu OHY; Pollak MN; Azoulay L
Epidemiology; 2018 Mar; 29(2):246-253. PubMed ID: 29283894
[TBL] [Abstract][Full Text] [Related]
2. Incretin based drugs and risk of cholangiocarcinoma among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OH; Faillie JL; Montastruc F; Platt RW; Bouganim N; Azoulay L
BMJ; 2018 Dec; 363():k4880. PubMed ID: 30518618
[TBL] [Abstract][Full Text] [Related]
3. Incretin based drugs and the risk of pancreatic cancer: international multicentre cohort study.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Juurlink DN; Targownik LE; Turin TC; Paterson JM; Ernst P;
BMJ; 2016 Feb; 352():i581. PubMed ID: 26888382
[TBL] [Abstract][Full Text] [Related]
4. Glucagon-like peptide-1 analogues and risk of breast cancer in women with type 2 diabetes: population based cohort study using the UK Clinical Practice Research Datalink.
Hicks BM; Yin H; Yu OH; Pollak MN; Platt RW; Azoulay L
BMJ; 2016 Oct; 355():i5340. PubMed ID: 27797785
[TBL] [Abstract][Full Text] [Related]
5. Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus.
Faillie JL; Yu OH; Yin H; Hillaire-Buys D; Barkun A; Azoulay L
JAMA Intern Med; 2016 Oct; 176(10):1474-1481. PubMed ID: 27478902
[TBL] [Abstract][Full Text] [Related]
6. Incretin-based drugs and risk of lung cancer among individuals with type 2 diabetes.
Rouette J; Yin H; Yu OHY; Bouganim N; Platt RW; Azoulay L
Diabet Med; 2020 May; 37(5):868-875. PubMed ID: 32124472
[TBL] [Abstract][Full Text] [Related]
7. Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists.
Dawwas GK; Smith SM; Park H
Cardiovasc Diabetol; 2018 Jul; 17(1):102. PubMed ID: 30016946
[TBL] [Abstract][Full Text] [Related]
8. Examining the risk of depression or self-harm associated with incretin-based therapies used to manage hyperglycaemia in patients with type 2 diabetes: a cohort study using the UK Clinical Practice Research Datalink.
Gamble JM; Chibrikov E; Midodzi WK; Twells LK; Majumdar SR
BMJ Open; 2018 Oct; 8(10):e023830. PubMed ID: 30297350
[TBL] [Abstract][Full Text] [Related]
9. Association Between Incretin-Based Drugs and the Risk of Acute Pancreatitis.
Azoulay L; Filion KB; Platt RW; Dahl M; Dormuth CR; Clemens KK; Durand M; Hu N; Juurlink DN; Paterson JM; Targownik LE; Turin TC; Ernst P; ; Suissa S; Dormuth CR; Hemmelgarn BR; Teare GF; Caetano P; Chateau D; Henry DA; Paterson JM; LeLorier J; Levy AR; Ernst P; Platt RW; Sketris IS
JAMA Intern Med; 2016 Oct; 176(10):1464-1473. PubMed ID: 27479930
[TBL] [Abstract][Full Text] [Related]
10. Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.
Ueda P; Wintzell V; Melbye M; Eliasson B; Svensson AM; Franzén S; Gudbjörnsdottir S; Hveem K; Jonasson C; Svanström H; Pasternak B
Diabetologia; 2021 Oct; 64(10):2204-2214. PubMed ID: 34254177
[TBL] [Abstract][Full Text] [Related]
11. Use of incretin agents and risk of acute and chronic pancreatitis: A population-based cohort study.
Knapen LM; de Jong RG; Driessen JH; Keulemans YC; van Erp NP; De Bruin ML; Leufkens HG; Croes S; de Vries F
Diabetes Obes Metab; 2017 Mar; 19(3):401-411. PubMed ID: 27883260
[TBL] [Abstract][Full Text] [Related]
12. Incretin-based drugs and the risk of congestive heart failure.
Yu OH; Filion KB; Azoulay L; Patenaude V; Majdan A; Suissa S
Diabetes Care; 2015 Feb; 38(2):277-84. PubMed ID: 25205143
[TBL] [Abstract][Full Text] [Related]
13. Incretin-Based Drugs and Risk of Intestinal Obstruction Among Patients With Type 2 Diabetes.
Faillie JL; Yin H; Yu OHY; Herrero A; Altwegg R; Renoux C; Azoulay L
Clin Pharmacol Ther; 2022 Jan; 111(1):272-282. PubMed ID: 34587280
[TBL] [Abstract][Full Text] [Related]
14. Dipeptidyl peptidase-4 inhibitors and incidence of inflammatory bowel disease among patients with type 2 diabetes: population based cohort study.
Abrahami D; Douros A; Yin H; Yu OHY; Renoux C; Bitton A; Azoulay L
BMJ; 2018 Mar; 360():k872. PubMed ID: 29563098
[TBL] [Abstract][Full Text] [Related]
15. Incretin therapy and its effect on body weight in patients with diabetes.
Lind M
Prim Care Diabetes; 2012 Oct; 6(3):187-91. PubMed ID: 22613745
[TBL] [Abstract][Full Text] [Related]
16. Use of Dipeptidyl Peptidase-4 Inhibitors and New-onset Rheumatoid Arthritis in Patients with Type 2 Diabetes.
Douros A; Abrahami D; Yin H; Yu OHY; Renoux C; Hudson M; Azoulay L
Epidemiology; 2018 Nov; 29(6):904-912. PubMed ID: 30028343
[TBL] [Abstract][Full Text] [Related]
17. Use of incretin agents and risk of pancreatic cancer: a population-based cohort study.
Knapen LM; van Dalem J; Keulemans YC; van Erp NP; Bazelier MT; De Bruin ML; Leufkens HG; Croes S; Neef C; de Vries F; Driessen JH
Diabetes Obes Metab; 2016 Mar; 18(3):258-65. PubMed ID: 26537555
[TBL] [Abstract][Full Text] [Related]
18. Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Faillie JL; Azoulay L; Patenaude V; Hillaire-Buys D; Suissa S
BMJ; 2014 Apr; 348():g2780. PubMed ID: 24764569
[TBL] [Abstract][Full Text] [Related]
19. Incretin-Based Drugs and the Incidence of Prostate Cancer Among Patients With Type 2 Diabetes.
Lu S; Yin H; Yu OHY; Azoulay L
Epidemiology; 2022 Jul; 33(4):563-571. PubMed ID: 35394977
[TBL] [Abstract][Full Text] [Related]
20. Incretin-based agents in type 2 diabetic patients at cardiovascular risk: compare the effect of GLP-1 agonists and DPP-4 inhibitors on cardiovascular and pancreatic outcomes.
Zhang Z; Chen X; Lu P; Zhang J; Xu Y; He W; Li M; Zhang S; Jia J; Shao S; Xie J; Yang Y; Yu X
Cardiovasc Diabetol; 2017 Mar; 16(1):31. PubMed ID: 28249585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]